Company intelligence / Profile preview

Omega Alpha SPAC

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Omega Alpha SPAC was a special purpose acquisition company formed to raise capital through an IPO and pursue a business combination, with an intended focus on healthcare, healthcare-related industries, and particularly biotechnology. It was sponsored by an affiliate of Omega Funds and listed on Nasdaq under the ticker OMEG. The company did not operate a therapeutic pipeline, develop drug candidates, or commercialize healthcare products; its business was to identify and merge with a target company. Omega Alpha SPAC was unable to complete an initial business combination within its required timeframe and liquidated in December 2022. As a result, it is best characterized as a healthcare-focused financial vehicle rather than an operating life sciences company.

Industry: Investors

Beyond the preview

Go deeper on Omega Alpha SPAC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omega Alpha SPAC.

Explore the full profile